

REMARKS

Applicants have added new claims 32-47. Thus, claims 18 and 32-47 are pending.

Claims 32-34 recite a method for determining the sulfonator status of an individual, wherein the method includes determining whether the subject contains a variant *SULT1A1*, *SULT1A2*, or *SULT1A3* nucleic acid. Claims 35-40 recite a method for predicting the therapeutic efficacy of a compound in a subject, wherein the method includes determining the sulfonator status of the subject. Claims 41-43 recite a method for predicting the therapeutic efficacy of a compound in a subject, wherein metabolism of the compound includes sulfonation, and wherein the method includes estimating the level of sulfotransferase activity in the subject. Claims 44-47 recite a method for estimating a dose of a compound for administration to a subject, wherein metabolism of the compound includes sulfonation, and wherein the method includes determining the sulfonator status of the subject. Support for claims 32-47 can be found in Applicants' specification at, for example, page 4, lines 1-4, and page 10, line 23 to page 11, line 7. No new matter has been added.

Applicants respectfully request that claims 18 and 32-47 be examined. Enclosed is a check for excess claim fees. Please apply any other charges or credits to deposit account 06-1050.

Respectfully submitted,

Date: July 9, 2004

Elizabeth N. Kaytor
Elizabeth N. Kaytor, Ph.D.
Reg. No. 53,103

Fish & Richardson P.C., P.A.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696